Kee-Jong Hong
Professor Gachon University School of Medicine
Kee-Jong Hong (BS, Seoul National Univ; MS, Seoul National Univ;PhD, Texas Tech Univ) is currently a Professor at the Department ofthe Microbiology, Gachon University School of Medicine, Korea, and aProgram Manager of Division for Health Security at Korea Advanced Research Project Agencyfor Health (ARPA-H) after finishing Korean National project for the mRNA Vaccine R&D,KmVAC(Korea mRNA Vaccine Initiative). He has conducted research and development relatedto the pandemic preparedness including Influenza, Coronavirus, Ebola virus, Nipah virus andBioterrorism pathogens such as Anthrax, tularemia. He worked for the Korean Dsease Controland Prevention Agency (KCDA) for 10 years as a government officer, also worked as a directorof the industrial research institutes including the Interpark BioConvergence (currently GradientBioConvergence) and the NKmax for another 7 years before joining the Gachon University. He isserving for the Korean Vaccine Society as a chair of publication committee, also serving for theKorean Society for Zoonoses as a vice president. In 2024, he was selected as a member ofScientific Advisory Committee for CEPI (Coalition for Epidemic Preparedness Innovations) andkeeps working till 2027.
Seminars
- Discussing opportunities for post pandemic preparedness
- Harnessing vaccine stockpile technology
- Demonstrating mobile manufacturing systems
With organizations such as the Korean Disease Control and Prevention Agency (KDCA), the Korean Ministry of Health, and The RIGHT Foundation, driving investment into next-generation mRNA technologies, collaboration between Korean and international stakeholders to achieve success has never been more critical. They will also be key to advancing regional manufacturing capabilities and ensuring equitable access to vaccines worldwide, particularly across low- and middle-income countries (LMICs).
Hear from vaccine experts as they shed light on strategies to overcome the next pandemic through RNA technology innovations including:
- How to develop key biopharma partnerships to achieve the impact on global vaccine equity?
- How to leverage best practices for mRNA vaccine R&D and local manufacturing in LMICs?
- Outlining current bottlenecks with scaling up to ensure regional capacity and global availability of mRNA vaccines
